The nutritional reality of GLP-1 therapy
Clinical evidence
What the research shows
480,825
adults studied across six clinical trials in a peer-reviewed narrative review
Urbina et al. · Clinical Obesity · 2026
13.6%
Developed Vitamin D deficiency within 12 months of starting GLP-1 therapy
26%+
Higher iron depletion rates in GLP-1 users compared to matched controls
54%
Of patients on GLP-1 therapy developed B12 deficiency in follow-up studies
39%
Of weight lost on GLP-1s can be lean muscle mass without nutritional intervention
Sources: Urbina et al., Clinical Obesity (2026) · Butsch et al., Obesity Pillars (2025) · Melis et al., Diabetes, Obesity and Metabolism (2025)
Ingredient evidence
Why each ingredient is here
Vitamin B12
1,125% DVGLP-1 therapy reduces B12 absorption. Deficiency causes the persistent fatigue most users report. High dose ensures adequate levels even with compromised absorption.
Biotin
1,000% DVRapid weight loss triggers telogen effluvium — temporary hair shedding that begins 2-4 months into therapy. Biotin supports keratin production and follicle health.
Chromium picolinate
343% DVSupports blood sugar regulation during metabolic transition. We use picolinate — the most bioavailable form and most studied in clinical trials.
Zinc
136% DVListed as a key nutrient of concern for GLP-1 users. Supports immune function, skin integrity, and protein synthesis during body composition change.
Folate
167% DVReduced food volume means less folate from leafy greens. Critical for DNA repair, cellular turnover, and mood regulation.
Vitamin D3
50% DV13.6% of GLP-1 users develop D deficiency within 12 months. Our formula provides neccesary support.
Magnesium
12% DVSupports muscle function and sleep.